Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Ralmitaront

From Wikipedia, the free encyclopedia
Investigational antipsychotic
Pharmaceutical compound
Ralmitaront
Clinical data
Other namesRG-7906; RG7906; RO-6889450; RO6889450
Identifiers
  • 5-Ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC17H22N4O2
Molar mass314.389 g·mol−1
3D model (JSmol)
  • CCC1=C(C(=NN1)C(=O)NC2=CC=C(C=C2)[C@H]3CNCCO3)C
  • InChI=1S/C17H22N4O2/c1-3-14-11(2)16(21-20-14)17(22)19-13-6-4-12(5-7-13)15-10-18-8-9-23-15/h4-7,15,18H,3,8-10H2,1-2H3,(H,19,22)(H,20,21)/t15-/m1/s1
  • Key:XHHXGKRFUPEPFM-OAHLLOKOSA-N

Ralmitaront (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name; developmental code namesRG-7906 andRO-6889450) is aninvestigationalantipsychotic drug which was undergoing aPhase II clinical trial for the treatment ofnegative symptoms inschizophrenia andschizoaffective disorder, but the trial was discontinued due to lack of efficacy.[1][2][3][4] Another Phase II clinical trial targeting acutepsychotic symptoms of schizophrenia was also terminated for the same reason.[5] It is apartial agonist of theTAAR1 protein.[6] The medication is being developed by the pharmaceutical companyHoffmann-La Roche.[1] Ralmitaront had completedPhase I clinical trials.[1][7]

See also

[edit]

References

[edit]
  1. ^abc"Ralmitaront - Roche".AdisInsight. Springer Nature Switzerland AG.
  2. ^Gomes FV, Grace AA (April 2021)."Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention".International Journal of Molecular Sciences.22 (9): 4467.doi:10.3390/ijms22094467.PMC 8123139.PMID 33922888.
  3. ^Clinical trial numberNCT04512066 for "Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms" atClinicalTrials.gov
  4. ^"Roche Terminates Second Phase II Schizophrenia Trial".BioSpace. 2023-05-23. Retrieved2025-04-06.
  5. ^Clinical trial numberNCT03669640 for "A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder" atClinicalTrials.gov
  6. ^"Ralmitaront: Relationships: Trace Amine-Associated Receptor 1".Global Substance Registration System (GSRS). U.S. Food and Drug Administration.
  7. ^Clinical trial numberNCT02699372 for "The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers" atClinicalTrials.gov
TAAR1Tooltip Trace amine-associated receptor 1
Agonists
Endogenous
Exogenous
Antagonists
Inverse agonists
TAAR5Tooltip Trace amine-associated receptor 5
Agonists
Inverse agonists
Notes: (1) TAAR1 activity of ligands varies significantly between species. Some agents that are TAAR1 ligands in some species are not in other species. This navbox includes all TAAR1 ligands regardless of species. (2) See the individual pages for references, as well as theList of trace amines,TAAR, andTAAR1 pages.
See also:Receptor/signaling modulators


Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ralmitaront&oldid=1301025323"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp